Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. To meet the new diagnosed type 2 diabetes patients, never received oral hypoglycemic drugs or insulin therapy;~2. In accordance with the nonalcoholic fatty liver (NAFLD) criteria for the diagnosis of patients.~3. the level of HbA1c was 7 -10.0%;~4. age 18-70, body mass index 21-35kg/m2;~5. the subjects informed consent and signed the informed consent.~Exclusion Criteria:~1. type 1 diabetes or secondary diabetes;~2. suffering from other liver diseases, such as hepatitis, self - free liver, etc.~3. abnormal thyroid function (in the active period), or the need for long-term oral and intravenous glucocorticoids to treat patients;~4. patients with severe renal dysfunction or renal disease (eGFR\<60);~5. in those with abnormal liver function, Alanine transaminase(ALT) or Aspartate transaminase(AST) was more than 3 times the normal upper limit.~6. people with serious gastrointestinal diseases such as peptic ulcers and chronic diarrhea;~7. patients with severe cardiopulmonary disease, cerebrovascular disease or stents;~8. hemopoietic system diseases such as serious primary diseases, hemoglobin \< 100g/L or need regular transfusion treatment;~9. pregnant, breast-feeding, women of childbearing age who are unwilling to contraception during the study period;~10. chronic cardiac insufficiency, the classification of heart function III level and above;~11. uncontrolled malignant tumor, and the history of bladder cancer.~12. acute complications of diabetes;~13. the use of other drugs for diabetes and liver disease;~14. patients who had participated in other clinical studies within three months;~15. people who have known allergies to this kind of drugs are known.~16. it is impossible to guarantee the effect or the safety judgment of the drug or the person who is unable to cooperate with the mental illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Combination of Pioglitazone and Metformin Tablets (Type: EXPERIMENTAL): dosage form: tablet; dosage:15mg/500mg; frequency: the dose in week 1 is 15mg/500mg, once a day, increased to 15mg/500mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;
- Metformin Hydrochloride Tablets (Type: ACTIVE_COMPARATOR): dosage form: tablet; dosage: 850mg; frequency: the dose in week 1 is 850mg, once a day, increased to 850mg in the second week, twice a day and maintain this dose to 24 weeks duration: 24 weeks; type: oral;

Based on this trial design, predict the completion outcome and termination type (if applicable).